The mean age for patients and controls was 8.2 +/- A 4.5 and 9.6 +/- A 4.2 years, respectively (p > 0.05). QTc dispersion significantly increased after anthracycline treatment (p = 0.02). TDI showed decreased SB273005 E’ velocity (p < 0.001) and E’/A’ ratio (p < 0.001) at lateral tricuspid annulus segment in TG-I, and these findings continued in TG-II and -III. In addition, S’ velocity decreased in TG-I, -II, and -III at lateral mitral annulus (10.5 +/- A 2.6 cm/s, p < 0.05; 9.9 +/- A 2.2 cm/s, p < 0.001; and 10.1 +/- A 2.3 cm/s, p < 0.01, respectively). However, decrease in left-ventricular

ejection fraction was statistically significant in TG-II and -III (p < 0.001). Although myocardial performance index was significantly increased in all treatment groups in both segments, it was primarily due to significant increases in isovolumic relaxation time at the lateral tricuspid annulus and isovolumic contraction time at the lateral mitral annulus. Abnormalities in diastolic function in right ventricle and systolic function in the left ventricle were observed even with a cumulative anthracycline dose < 120 mg/m(2) by TDI. In addition, anthracycline treatment led to an increase in QTc dispersion.”
“One new triterpenoid olean-18-ene-1 beta,

2 alpha, 3 beta-triol (1) along with four known compounds were isolated from the chloroform extract of the aerial part of Salvia atropatana Bunge. The known compounds selleck chemicals check details were two flavonoids, 5-hydroxy-7,4′-dimethoxyflavone (2) and 5-hydroxy-6,7,4′-trimethoxyflavone (3), an abietane-type diterpene namely taxodione (4) and a phytosterol namely gamma-sitosterol (5). The structure of (1) was elucidated by comprehensive spectroscopic analysis including electron ionization-mass spectra (EI-MS), H-1 NMR, C-13 NMR, distortionless enhancement by polarization transfer (DEPT), H, H correlation spectroscopy (COSY), heteronuclear

multiple quantum coherence (HMQC) and heteronuclear multiple bond correlation (HMBC). The structure of known compounds 2-5 were identified by comparison of their spectral data with those reported in the literature.”
“Statins (HMG-CoA reductase inhibitors) may decrease inflammation in postacute Kawasaki disease (KD) complicated by coronary artery aneurysm (CAA) and promote vascular remodeling. There are limited data on their safety in young children. Twenty patients with CAAs after KD (median CAA z-score = +25) were treated with 5/10 mg atorvastatin daily for a median of 2.5 years (range 0.5-6.8) starting at a median of 2.3 years (range 0.3-8.9) after acute KD (median age 9.3 years [range 0.7-14.3]). Compliance with treatment was excellent: only one patient reported minor side effects (joint pain, no change in medication). Average total cholesterol before atorvastatin was 3.73 +/- A 0.84 mmol/L and after atorvastatin was 3.21 +/- A 0.46 mmol/L (relative decrease -14 %, p = 0.02); low-density lipoprotein cholesterol was 1.99 +/- A 0.